Q3 revenue and profitability exceeded expectations, driven by strong growth in recurring revenue businesses and Multiomics in Europe and China, while North America showed modest improvement. FY 2026 guidance was raised, but the outlook remains cautious due to uneven demand and ongoing headwinds in Sanger Sequencing and capital equipment.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.